New treatment for multiple sclerosis has been approved by EU regulatory body


A  new treatment for multiple sclerosis and the result of over three decades of research in Cambridge University, UK, was approved on the 17 September by the EU agency responsible for regulating new drugs. The drug, lemtuzumab (brand name Lemtrada), was previously called Campath-1H (“Cambridge Pathology 1st Human”) and is indicated for the treatment of multiple sclerosis. This video explores the history of Campath-1H.